NHS Trust Adopts Products

Advanced Medical Solutions Grp PLC
29 March 2006


For immediate release                                              29 March 2006



                      Advanced Medical Solutions Group plc

                            ('AMS' or 'the Company')



                 Major NHS Trust implements ActivHeal(R) range



Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global
woundcare technology company, today announces that the Oxford Radcliffe
Hospitals NHS Trust (ORH) has implemented the ActivHeal(R) advanced woundcare
range as its first choice  dressings.  The ORH consists of four hospitals - the
John Radcliffe and Churchill Hospitals, Headington, the Radcliffe Infirmary,
Oxford, and the Horton Hospital in Banbury.  Significant changes to the Trust's
formulae for woundcare dressings were introduced under the direction of the
Chief Nurse working in conjunction with Pharmacy to implement ActivHeal(R).



ActivHeal(R) is a value range of advanced woundcare dressings specifically
designed by AMS for use on routine wounds.  Independent technical and clinical
assessment has shown that the ActivHeal(R) products are equivalent to the
branded versions in performance whilst significantly reducing the cost of
treatment.



ActivHeal(R) offers real and immediate savings to the NHS of the order of £25m
per year across England and Scotland.  These savings on the treatment of routine
wounds are available to ensure that the new technologies needed for problematic
cases are affordable within current budgets.  As a UK based R&D and
manufacturing company, AMS is also involved in delivering innovative woundcare
technologies to the market through its branded marketing and distribution
partners.



Commenting on this announcement Dr. Don Evans, Chief Executive of AMS, stated:



'I am delighted that we have added a major teaching centre such as the Oxford
Radcliffe to the growing number of Hospital and Primary Care Trusts that have
adopted the ActivHeal(R) offering as a way of managing costs without
compromising patient care.'



The Oxford Radcliffe Hospitals NHS Trust Chief Nurse, Julie Hartley-Jones,
added:



'There is no clinical evidence to support the view that any one dressing within
the categories addressed by ActivHeal(R) is more effective than another of the
same type.  Therefore, it has been agreed that the ActivHeal(R) range will be
implemented with immediate effect since the use of these products offer the
Oxford Radcliffe Hospitals savings of 30%, at a time of severe funding pressure.



'These changes have the approval of the Trust Product Selection Group, the
Medicines Advisory Committee and the Tissue Viability Nurse Consultant.'









For further information, please contact:


Advanced Medical Solutions Group plc                  Tel : [phone]
Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com


Buchanan Communications                               Tel: [phone]
Mark Court, Mary-Jane Johnson



Notes to Editors:



Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $13 billion global woundcare market.



Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.



In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS' resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.



The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives that offer benefits over sutures and
staples for closing wounds sold direct to hospitals or through distributors.



AMS' technology and products currently serve the majority of the key global
markets and strategic partners.








                      This information is provided by RNS
            The company news service from the London Stock Exchange